Latest / The Bill Handel Show / Where Did Cheap Restaurants Go? | ‘Medical News’ with Dr. Jim Keany

Transcript

Where Did Cheap Restaurants Go? | ‘Medical News’ with Dr. Jim Keany · The Bill Handel Show

• 0:01
  Speaker 1: You're listening to Bill Handel On Demand from KFI AM 640.
• 0:04
  Speaker 2: Welcome to my house.
• 0:09
  Speaker 1: Baby, take control now.
• 0:13
  Speaker 2: We can't even slow down. KFI AM 640.
• 0:16
  Speaker 3: Bill Handel here. It is a Wednesday morning September.
• 0:19
  Speaker 2: Excuse me. September. Oh, I can't believe it. I got.
• 0:25
  Speaker 4: Hold on.
• 0:26
  Speaker 1: Everything okay, Bob?
• 0:28
  Speaker 3: No, I'm chewing on a Costco biscotti. You've seen those
• 0:33
  Speaker 3: and those small biscottis in that big package. I love those,
• 0:35
  Speaker 3: but they're very dry. And I'm grabbing one of those.
• 0:39
  Speaker 2: In any case... It's okay.
• 0:40
  Speaker 1: No, no, don't let us bother you. You go ahead
• 0:42
  Speaker 1: and swallow. Get some of that Diet Coke in you.
• 0:45
  Speaker 2: I just had Diet Coke, which I also bought from Costco,
• 0:47
  Speaker 2: of course.
• 0:48
  Speaker 4: Oh, boy.
• 0:48
  Speaker 3: Okay. In the meantime, some of the stories we are
• 0:51
  Speaker 3: looking at... Thank you for being so patronizing.
• 0:54
  Speaker 2: In the meantime... Some of the stories we're.
• 0:57
  Speaker 3: Looking at, President Xi Jinping is meeting with President Trump,
• 1:02
  Speaker 3: three-day visit with a state dinner, which is no small
• 1:05
  Speaker 3: deal because that is the ultimate that the President of
• 1:08
  Speaker 3: the United States or basically anybody can or any world
• 1:12
  Speaker 3: leader can honor another world leader as the state dinner,
• 1:16
  Speaker 3: which is why he is building that great, big, beautiful
• 1:19
  Speaker 3: ballroom because he wants to invite people A thousand people.
• 1:23
  Speaker 3: Have you noticed that? I'm going to digress for a minute.
• 1:26
  Speaker 3: When George Bush had a few state dinners, they put
• 1:29
  Speaker 3: that huge white tent outside because they wanted several hundred
• 1:35
  Speaker 3: or several or a thousand people or more. And the
• 1:38
  Speaker 3: president is saying we don't have a space, which is true.
• 1:41
  Speaker 3: So anyway, that's one of the reasons he did that. Now,
• 1:47
  Speaker 3: a simple fact, L.A., Southern California, desperate for housing. So
• 1:52
  Speaker 3: you would think that the multi-story buildings would be going
• 1:57
  Speaker 3: up because they're all being zoned. The residential zoning has
• 2:02
  Speaker 3: now been changed to multifamily zoning.
• 2:04
  Speaker 2: Are you ready for this?
• 2:06
  Speaker 3: Multifamily values have plunged nearly 30% values of housing.
• 2:12
  Speaker 2: And why?
• 2:13
  Speaker 3: Because developers said new apartments no longer pencil out.
• 2:17
  Speaker 2: They just can't. There's no way they're ever going to
• 2:19
  Speaker 2: make money.
• 2:20
  Speaker 3: Higher interest rates, the fees, the mansion tax that was
• 2:24
  Speaker 3: passed have just gotten rid of profit.
• 2:27
  Speaker 2: So where are they turning to? ADUs, single-family homes.
• 2:32
  Speaker 3: ADUs is a unit, one, where a multifamily dwelling, you
• 2:37
  Speaker 3: buy a piece of land or someone buys a piece
• 2:39
  Speaker 3: of land and can put, I don't know, 15, 20,
• 2:42
  Speaker 3: 25 units. They're not building those because it just doesn't
• 2:46
  Speaker 3: make sense. And so 30% drop in building, well, it
• 2:53
  Speaker 3: seems shocking even five years ago. But let me give
• 2:58
  Speaker 3: you the average sales price per unit in new and
• 3:03
  Speaker 3: in existing multifamily buildings in L.A.
• 3:06
  Speaker 4: County, $ 400, 000.
• 3:06
  Speaker 2: That was then. That was 2022. 2026 is down to $ 280, 000.
• 3:08
  Speaker 2: The state is begging people to build more homes.
• 3:19
  Speaker 3: Karen Bass implemented a faster permitting process earlier this year,
• 3:23
  Speaker 3: and it really flies. It's gone from 18 months to
• 3:25
  Speaker 3: 16 months to get a permit, right? I mean, it's
• 3:28
  Speaker 3: still insane. There are a bunch of developers are saying,
• 3:33
  Speaker 3: you know, building new apartments just isn't.
• 3:35
  Speaker 2: Good right now. Can't do it.
• 3:38
  Speaker 3: Taxes eat through profits. Projects don't pencil. The developers are
• 3:43
  Speaker 3: building the smaller, safer projects, townhomes. as opposed to these taller,
• 3:49
  Speaker 3: denser developments that experts say the cities absolutely need. We
• 3:53
  Speaker 3: need that. But look at the market for building new
• 3:57
  Speaker 3: apartment buildings. No one is thriving. Developers aren't making money
• 4:01
  Speaker 3: at all. Tenants are dealing with rents higher than virtually
• 4:05
  Speaker 3: any other city in the country. Now, earlier this year,
• 4:08
  Speaker 3: rents dropped to a four-year low, but they're up again
• 4:12
  Speaker 3: because you have pent-up demand. There's no building going on.
• 4:16
  Speaker 3: Decades of underbuilding because it's so difficult to build. Housing
• 4:23
  Speaker 3: in neighborhoods still too expensive for renters, out of reach
• 4:27
  Speaker 3: for aspiring buyers. I've told you many times that today
• 4:31
  Speaker 3: to get a new home is crazy. A million-dollar home,
• 4:34
  Speaker 3: which is nothing, basically.
• 4:36
  Speaker 2: You need $ 200, 000 down.
• 4:36
  Speaker 3: Who the hell has $ 200, 000 in cash to buy a
• 4:38
  Speaker 3: home and still have an $ 800, 000 mortgage at 7%? which
• 4:49
  Speaker 3: is exactly what you pay right now. So decline in
• 4:55
  Speaker 3: construction for years. The executive vice president at Kidder Matthews,
• 5:01
  Speaker 3: which is one of the firms that study this, says
• 5:05
  Speaker 3: most developers I speak to are pencils down, and they
• 5:10
  Speaker 3: have been for quite a while. It's just no fun.
• 5:16
  Speaker 2: It really isn't.
• 5:18
  Speaker 3: All right, if you're a developer, and developers make all
• 5:21
  Speaker 3: the money in the world, and so what happens? Well,
• 5:24
  Speaker 3: let's tax developers even more. Tax wealthy people, of course.
• 5:28
  Speaker 3: You know there are so many fees that they're running
• 5:31
  Speaker 3: out of names for fees. It's now just number. Fee
• 5:35
  Speaker 3: number 46, fee number 47. And to show you how
• 5:38
  Speaker 3: ridiculous it is, San Bernardino has a kangaroo rat tax.
• 5:48
  Speaker 3: honest to God, because the kangaroo rat is indigenous to
• 5:53
  Speaker 3: San Bernardino County. And if you're building in San Bernardino County,
• 5:57
  Speaker 3: you have all the permits and everything you have to
• 6:00
  Speaker 3: go through. And there is a per square foot tax,
• 6:04
  Speaker 3: building tax to keep the habitat of the kangaroo rat.
• 6:11
  Speaker 3: That's the kangaroo rat tax. It's very, very difficult. All right,
• 6:16
  Speaker 3: we're going to switch gears. And this is something that
• 6:19
  Speaker 3: I have been harping about with Neil, and that is
• 6:22
  Speaker 3: the restaurants. And it's out of the Wall Street Journal.
• 6:25
  Speaker 3: And the question is, where did all the cheap restaurants go?
• 6:28
  Speaker 3: And before I get to Neil and ask that question,
• 6:33
  Speaker 3: I used to not even pay attention to going out
• 6:35
  Speaker 3: to a restaurant. It was, I just didn't care. I mean,
• 6:39
  Speaker 3: a good restaurant to me was $ 40, $ 50 a head.
• 6:41
  Speaker 3: That to me was a high-end restaurant. Today, $ 40 a
• 6:49
  Speaker 3: head is lunch at a moderately priced restaurant. And I'm going,
• 6:55
  Speaker 3: wait a minute. Frankly, I just say I'm not going
• 6:58
  Speaker 3: out to dinner. I'll be driving around with Linz and
• 7:01
  Speaker 3: we say, oh, let's go grab something to eat. I
• 7:03
  Speaker 3: do not want to spend $ 80 for lunch. It's that simple.
• 7:07
  Speaker 3: So where did they all go? Do they even exist anymore, Neil?
• 7:13
  Speaker 3: And do they have a chance of opening up?
• 7:17
  Speaker 4: Not right now.
• 7:18
  Speaker 1: I mean, there are places that focus on inexpensive or
• 7:23
  Speaker 1: less expensive food, but you can't, everything's gone up right now.
• 7:28
  Speaker 2: You can't have.
• 7:30
  Speaker 1: Forced $ 20 an hour raises up from, you know, 15
• 7:36
  Speaker 1: or whatever it was. You can't have that happen immediately
• 7:41
  Speaker 1: where the government steps in and says, you have to
• 7:44
  Speaker 1: pay this much. for your, you know, the help that work.
• 7:50
  Speaker 4: Yeah.
• 7:50
  Speaker 2: For the people, the staff, the.
• 7:52
  Speaker 1: Crew, and have it not hit you, let alone the
• 7:55
  Speaker 1: cost of food. It's just, it's silly to think that
• 7:59
  Speaker 1: the food's going up in your own home and it's
• 8:01
  Speaker 1: not going to go up at a restaurant. It just,
• 8:04
  Speaker 1: they either are shuttering or they have to pass that
• 8:07
  Speaker 1: along to you.
• 8:07
  Speaker 2: They just do. Now at home, your food is going up.
• 8:11
  Speaker 3: I don't know, 8%, 8, 7%. And in restaurants, it's
• 8:18
  Speaker 3: going up a lot faster than that. I look at
• 8:21
  Speaker 3: meals that are literally double what they used to be
• 8:25
  Speaker 3: five years ago.
• 8:26
  Speaker 2: It's kind of crazy.
• 8:27
  Speaker 3: And even with the prices this high, restaurants are not
• 8:30
  Speaker 3: necessarily passing on the increased cost.
• 8:34
  Speaker 2: Of doing business.
• 8:34
  Speaker 1: Not the whole cost. But you also, this is not
• 8:38
  Speaker 1: how we think. When you're cooking at home, you're thinking
• 8:42
  Speaker 1: of the cost of the food. But at a restaurant,
• 8:45
  Speaker 1: they're thinking of the cost of the food, the condiments,
• 8:48
  Speaker 1: the oil that's going in there, the electricity, the gas,
• 8:52
  Speaker 1: all that is and the cost of the employees, all
• 8:56
  Speaker 1: that's wrapped up into your food. So you're not calculating
• 8:59
  Speaker 1: that when you're cooking at home because you're free labor
• 9:03
  Speaker 1: and you don't think about your electricity. But if you
• 9:05
  Speaker 1: broke it all down, you're paying way more than you
• 9:08
  Speaker 1: think for the food you're making at home.
• 9:11
  Speaker 3: And so is it fair to say, well, I'm going
• 9:14
  Speaker 3: to ask you the question, restaurants, are they simply declining
• 9:20
  Speaker 3: that we're seeing fewer restaurants out there?
• 9:25
  Speaker 1: Well, yes, there are some that have still not come
• 9:29
  Speaker 1: out of the hole that was built by, you know,
• 9:34
  Speaker 1: the government during COVID, the shutdown and everything like that.
• 9:37
  Speaker 1: They're still barely crawling out of that if they are.
• 9:40
  Speaker 1: And there have been some that in City Hall that
• 9:45
  Speaker 1: have fought for local restaurants to still be able to
• 9:49
  Speaker 1: seat outside and do things that help them. That gives
• 9:52
  Speaker 1: them a bigger footprint. But otherwise, these places are struggling
• 9:59
  Speaker 1: to make anything happen. The higher margin stuff is things
• 10:04
  Speaker 1: like alcohol and dessert. And more people are in GLP-1s
• 10:08
  Speaker 1: and maybe not eating dessert. They want the proteins, which
• 10:12
  Speaker 1: are going up in cost. And they're not drinking as much.
• 10:16
  Speaker 1: The current generation is starting to drink again. But the
• 10:19
  Speaker 1: last one, uh, uh, stop drinking.
• 10:23
  Speaker 3: How about the high, high end places, which I've been
• 10:26
  Speaker 3: to a couple of times in my life where you're
• 10:29
  Speaker 3: talking a hundred, $ 150 a person. I mean, those are
• 10:33
  Speaker 3: bucket list restaurants and you call up, uh, and it is, uh,
• 10:39
  Speaker 3: you can't get in.
• 10:39
  Speaker 1: And well, yeah, if you go to a high end restaurant,
• 10:44
  Speaker 1: but most of them, gosh, you go into Beverly Hills
• 10:48
  Speaker 1: or you go to Malise or you go to these
• 10:51
  Speaker 1: high-end restaurants, they were already paying better than other restaurants
• 10:54
  Speaker 1: for one. So the cost of food is going to
• 10:59
  Speaker 1: change things, but they're probably more stable in one sense.
• 11:06
  Speaker 1: I hate saying that across the board, but In one sense,
• 11:09
  Speaker 1: they're probably more stable because they were already giving you
• 11:11
  Speaker 1: a high-end experience that you were paying for. It's the
• 11:14
  Speaker 1: other ones that you're going to see, the things that
• 11:17
  Speaker 1: you expect to be cheaper that are going up, your
• 11:21
  Speaker 1: diners and things like that. We talked some weeks ago
• 11:24
  Speaker 1: about how 24-hour diners are shuttering here in LA.
• 11:31
  Speaker 3: Yeah, they're so much fun. And so we'll talk about
• 11:34
  Speaker 3: this again. And sure, Neil talks about it on his
• 11:37
  Speaker 3: show quite often.
• 11:38
  Speaker 4: Yeah, it's unfortunate.
• 11:39
  Speaker 3: Yeah, Fork Report. Neil is two to five Saturdays. See,
• 11:44
  Speaker 3: I got to plug in there. All right, coming up, Dr.
• 11:47
  Speaker 3: Jim Keeney. And Jim, who is the chief medical officer
• 11:51
  Speaker 3: for Dignity St. Mary Medical Center.
• 11:53
  Speaker 2: In Long Beach.
• 11:55
  Speaker 3: We've got some topics that we're going to share. GLP-1
• 11:59
  Speaker 3: is one of them. The breast cancer pill is another one.
• 12:04
  Speaker 3: Interesting stuff. And supplement patches. Guys, I know they say
• 12:11
  Speaker 3: that your schwanz could get bigger with a supplement patch.
• 12:14
  Speaker 2: Believe me, I've tried all of them. They don't work.
• 12:18
  Speaker 2: We don't need no stinking patches. Yeah, that's true. Okay.
• 12:22
  Speaker 3: Wednesday, last two segments of the show. It's a medical
• 12:26
  Speaker 3: news with Dr. Jim Keeney, Jim chief medical officer for dignity, St.
• 12:30
  Speaker 3: Mary medical center in long beach and a board certified
• 12:35
  Speaker 3: ER doctor.
• 12:37
  Speaker 2: Jim, thanks for joining us.
• 12:39
  Speaker 3: And okay, here is something that so many people are
• 12:45
  Speaker 3: on and that's the GLP one drugs show. And now
• 12:49
  Speaker 3: we're hearing that lawsuits are starting to fly based on
• 12:55
  Speaker 3: the fact that for some reason, a number of GLP-1
• 12:59
  Speaker 3: patients are starting to do impressions of Ray Charles. And
• 13:04
  Speaker 3: so what's going on with this vision loss? See how
• 13:10
  Speaker 3: that worked? It's a good connection.
• 13:12
  Speaker 4: Yeah.
• 13:13
  Speaker 2: Okay. Thank you, Jim, for understanding.
• 13:15
  Speaker 4: I got that.
• 13:16
  Speaker 2: Yeah.
• 13:16
  Speaker 4: So so this is it's interesting, right? Because and it's
• 13:20
  Speaker 4: hard because every time you talk about stuff like this,
• 13:22
  Speaker 4: it's statistics and nobody's really interested in statistics. Right. So
• 13:27
  Speaker 4: what it looks like is these there's an association between
• 13:31
  Speaker 4: being on Ozempic and a doubling of your chances of
• 13:36
  Speaker 4: this thing happening. So so this can happen to people
• 13:38
  Speaker 4: without being on Ozempic. And if people that are on it,
• 13:42
  Speaker 4: it has a double the chance. We don't know whether
• 13:44
  Speaker 4: that means that the Ozempic doubled the chance or the
• 13:47
  Speaker 4: things that's selected for the group of people who take Ozempic,
• 13:51
  Speaker 4: like being overweight, having high blood pressure, having sleep apnea.
• 13:55
  Speaker 4: Are those the risk factors that actually caused it? And
• 13:57
  Speaker 4: that's why this selected group has doubled the chance. It's
• 14:00
  Speaker 4: an extremely rare thing. We're talking about two to four
• 14:04
  Speaker 4: people per hundred thousand will get this. So that means
• 14:09
  Speaker 4: 996,000 on it won't get it. All right.
• 14:11
  Speaker 3: So your chances, it's one of those where if you
• 14:13
  Speaker 3: have a one in a hundred thousand chance and all
• 14:17
  Speaker 3: of a sudden you've doubled it, it's now two out
• 14:19
  Speaker 3: of a hundred thousand chance. So those are minuscule numbers.
• 14:24
  Speaker 3: And yet does medical science take that stuff seriously when
• 14:27
  Speaker 3: the numbers are that low?
• 14:29
  Speaker 4: Yeah, absolutely. Because, I mean, what we'd like to know,
• 14:31
  Speaker 4: is there a true, there's an association for sure. It
• 14:34
  Speaker 4: seems like it does double the chances. So now, is
• 14:38
  Speaker 4: it a cause? Does the ozempic actually cause it or
• 14:41
  Speaker 4: is it the other things that cause it? There is
• 14:43
  Speaker 4: no proof of that. The National Association that deals with
• 14:48
  Speaker 4: this particular disease has come out and said, you know,
• 14:51
  Speaker 4: we see an association for sure. Well, not even for sure.
• 14:54
  Speaker 4: Some studies don't show an association. There's no increase in
• 14:58
  Speaker 4: some of the studies. And we're talking about studies that
• 15:00
  Speaker 4: are retrospective studies looking at like between two and four
• 15:04
  Speaker 4: million people. So, you know, they have good numbers, but
• 15:09
  Speaker 4: sometimes it shows an association. Sometimes it doesn't. It just
• 15:12
  Speaker 4: remains to be seen. And it's going to be very
• 15:14
  Speaker 4: hard when you have a very rare side effect. to
• 15:17
  Speaker 4: try and tease out whether the drug caused it or
• 15:20
  Speaker 4: something else caused it is going to take huge numbers.
• 15:23
  Speaker 4: And so it's going to be very difficult to figure out.
• 15:26
  Speaker 4: But when you look at the risks of obesity, it's
• 15:30
  Speaker 4: pretty clear that taking this risk, right? We always take risks.
• 15:34
  Speaker 4: You decide to go on the freeway because you need
• 15:36
  Speaker 4: to get to work in an efficient manner and you
• 15:39
  Speaker 4: know there's a chance you're getting in a car wreck
• 15:40
  Speaker 4: on that freeway, one that could even kill you. But
• 15:42
  Speaker 4: you take that chance because, you know, the risk-benefit ratio
• 15:46
  Speaker 4: plays out. And I think in this case, I would
• 15:49
  Speaker 4: not stop taking Ozempic just because of this.
• 15:51
  Speaker 3: FDA approved breast cancer pill. Considering breast cancer is such
• 15:55
  Speaker 3: a huge problem in the United States, how big a
• 15:58
  Speaker 3: deal is this?
• 15:59
  Speaker 2: I mean, is this really for real?
• 16:03
  Speaker 4: Oh, yeah. This is for real. It's a big deal,
• 16:06
  Speaker 4: but for a very small select group of patients, right? So,
• 16:11
  Speaker 4: you know how we can slice and dice these different
• 16:13
  Speaker 4: types of cancers into different categories as far as, you know,
• 16:17
  Speaker 4: if you're HR positive, HERS2 negative, that's what in this
• 16:23
  Speaker 4: group we're looking for for this pill. And they have
• 16:25
  Speaker 4: to have locally advanced or metastatic breast cancer. Then they
• 16:30
  Speaker 4: have to have a mutation. after starting chemo, It is
• 16:36
  Speaker 4: an ESR1 resistant mutation. So that's, you know, this is
• 16:39
  Speaker 4: highly specific. But here's the big deal is that before
• 16:43
  Speaker 4: we used to do, we used to treat. Then we
• 16:45
  Speaker 4: used to take a scan. We would see no growth
• 16:48
  Speaker 4: or we would see new growth. And then all of
• 16:50
  Speaker 4: a sudden we would say, okay, the treatment didn't work.
• 16:52
  Speaker 4: We're going to change the treatment. And we do that
• 16:54
  Speaker 4: cycle over and over again. This is now we treat.
• 16:57
  Speaker 4: We do a blood test to see if there's molecular
• 17:01
  Speaker 4: resistance building up in the DNA and And then we
• 17:04
  Speaker 4: change the treatment before we ever see any new visible tumor.
• 17:08
  Speaker 4: And the question is, does that really work? Does that
• 17:10
  Speaker 4: reduce the growth for the cancer? It does. And in
• 17:14
  Speaker 4: these individuals, it definitely worked. And that's what, so they had,
• 17:18
  Speaker 4: they looked at 3000 cases that were underwent this testing
• 17:23
  Speaker 4: and they ended up with 315 patients. So about 10%
• 17:26
  Speaker 4: will start in that first category and transition to the
• 17:29
  Speaker 4: being the mutation that's fixed by this pill. And and
• 17:33
  Speaker 4: then they gave him the pill and it did increase
• 17:37
  Speaker 4: mean survival. But, you know, very specific.
• 17:40
  Speaker 2: Yeah.
• 17:40
  Speaker 4: But very specific.
• 17:41
  Speaker 2: You see, that's the question I ask. Where is this
• 17:44
  Speaker 2: a big deal?
• 17:45
  Speaker 3: Because I'm talking numbers and people who get brands, breast cancer,
• 17:49
  Speaker 3: and it's enormous number of women and occasionally a man.
• 17:54
  Speaker 3: And if I have breast cancer, I'm jumping up and
• 17:58
  Speaker 3: down and saying there's a new breast cancer pill.
• 18:01
  Speaker 2: Is it so specific?
• 18:03
  Speaker 3: Is it so limited that the number of breast cancer
• 18:08
  Speaker 3: patients are, well, frankly, minuscule relative to what the number
• 18:13
  Speaker 3: of breast cancer cases out there, period?
• 18:18
  Speaker 4: Yeah, I mean, so it's not a big number. It's
• 18:20
  Speaker 4: not the majority, right? I don't have an exact percentage
• 18:23
  Speaker 4: of how many people are going to fit into this category,
• 18:25
  Speaker 4: but it is people right now with a very limited
• 18:30
  Speaker 4: lifespan because they have advanced breast cancer that's metastatic and resistant. So,
• 18:37
  Speaker 4: the issue is that as we learn about breast cancer,
• 18:40
  Speaker 4: we learn around the edges, right? Because we are more
• 18:43
  Speaker 4: willing to push harder and test unproven therapies on people
• 18:48
  Speaker 4: that we know don't have a long life span. And
• 18:51
  Speaker 4: those people are willing to be tested on. And so,
• 18:54
  Speaker 4: you know, that's what we're learning and we're moving that
• 18:56
  Speaker 4: edge back. So, in the future, could we... eventually get
• 19:00
  Speaker 4: to a point where we don't have to wait for
• 19:02
  Speaker 4: tumor growth on an x-ray before we can do a
• 19:05
  Speaker 4: blood test and figure out whether the cancer treatment is
• 19:07
  Speaker 4: working or not working. That's the big change, and that
• 19:10
  Speaker 4: will be the big deal in the future. But right now,
• 19:13
  Speaker 4: it's just for a select few.
• 19:15
  Speaker 3: Okay, and then we'll do a final question here. The
• 19:19
  Speaker 3: fact that this works for very few people under very
• 19:23
  Speaker 3: specific circumstances, does that lead logically to expanding the treatment
• 19:29
  Speaker 3: based on this research to create more and more drugs
• 19:34
  Speaker 3: for more and more people?
• 19:37
  Speaker 4: Yeah, absolutely. Absolutely. This particular drug because of the mechanism.
• 19:41
  Speaker 4: So the mechanism is that, you know, we put people
• 19:44
  Speaker 4: on estrogen inhibitors because we know the estrogen hits a
• 19:47
  Speaker 4: receptor and then it makes the cancer grow. And what
• 19:51
  Speaker 4: happens in this mutation is the receptor actually mutates. So
• 19:54
  Speaker 4: we no longer need the estrogen to activate the receptor
• 19:57
  Speaker 4: and make the tumor grow, which is crazy. I mean,
• 20:00
  Speaker 4: it's so crazy how smart these cancers are for cells.
• 20:03
  Speaker 4: And so, this one is very specific that it actually
• 20:08
  Speaker 4: wipes out that receptor. So, it goes straight for the
• 20:10
  Speaker 4: receptor and wipes it out. I guess it's possible that
• 20:13
  Speaker 4: could be expanded in the future for any receptor-positive cancer
• 20:18
  Speaker 4: that we could go after that specific receptor. You know,
• 20:22
  Speaker 4: it is interesting, and like I said, I think it
• 20:26
  Speaker 4: helps for future, but right now it is a smaller
• 20:29
  Speaker 4: percentage of cancer patients.
• 20:30
  Speaker 3: Okay, so real quickly, is there anything in the future,
• 20:34
  Speaker 3: I mean, the magic bullet for cancer, because there's so
• 20:38
  Speaker 3: many hundreds of cancers out there, and it looks like
• 20:40
  Speaker 3: the treatments are very specific to a given cancer.
• 20:45
  Speaker 4: Well, I mean, as we develop these monoclonal antibodies that
• 20:48
  Speaker 4: can go after very specific molecular targets, and at the
• 20:53
  Speaker 4: same time now we're developing the ability to be able
• 20:56
  Speaker 4: to do DNA testing and get very specific DNA on
• 21:02
  Speaker 4: each of these individual different cancers. Even though we say
• 21:06
  Speaker 4: breast cancer, we could be talking about hundreds of different
• 21:08
  Speaker 4: variations of So, the timing is right where we both
• 21:13
  Speaker 4: have targeted magic bullets that can go after a molecular target,
• 21:18
  Speaker 4: and we have the ability to identify specific molecular targets. So, yeah,
• 21:23
  Speaker 4: I think we're at an inflection point where these things
• 21:26
  Speaker 4: are going to expand and grow. They're going to be
• 21:28
  Speaker 4: ridiculously expensive. So, that's the other question is, can we
• 21:32
  Speaker 4: afford the treatment? Once we get this... and it shows
• 21:36
  Speaker 4: that it saves lives, but it costs, you know, half
• 21:38
  Speaker 4: a million dollars to save a life. Are we going
• 21:41
  Speaker 4: to be able to afford that?
• 21:43
  Speaker 3: Yeah. And there's very few people that are worth half
• 21:45
  Speaker 3: a million dollars as far as I'm concerned.
• 21:48
  Speaker 2: Uh, just, uh, no thanks. You know, just die. All right, Jim, uh,
• 21:52
  Speaker 2: we're done, uh, on a Wednesday as we usually are. Uh,
• 21:55
  Speaker 2: thank you.
• 21:55
  Speaker 3: We'll talk again next Wednesday and you and I will
• 21:58
  Speaker 3: probably talk, uh, in the next few days.
• 22:00
  Speaker 2: Uh, Absolutely. All right, Jim, thank you. And that's it.
• 22:03
  Speaker 3: We are done, guys. Wednesday is done. I come back tomorrow.
• 22:08
  Speaker 3: Tomorrow's my last day before I go on vacation. And
• 22:11
  Speaker 3: so Neil will be taking over for me, so you'll
• 22:14
  Speaker 3: probably get a real show.
• 22:16
  Speaker 2: So tomorrow morning, it's Will, who, never mind.
• 22:21
  Speaker 3: You've been listening to The Bill Handel Show.
• 22:23
  Speaker 2: Catch my show Monday through Friday, 6 a.m.
• 22:25
  Speaker 3: To 9 a.m., and anytime on demand on the iHeartRadio app.